• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Progenity, Inc.

    8/30/21 10:15:32 AM ET
    $PROG
    Specialty Chemicals
    Consumer Durables
    Get the next $PROG alert in real time by email
    SC 13G 1 tm2126414d1_sc13g.htm SC 13G

     

     

     

    CUSIP No:      74319F107

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. ____)*

     

    Progenity, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    74319F107

    (CUSIP Number)

     

    August 19, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No:      74319F107

     

      (1) NAMES OF REPORTING PERSONS
     
        CVI Investments, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Cayman Islands
         

    NUMBER OF (5) SOLE VOTING POWER
    SHARES
    BENEFICIALLY 0  
    OWNED BY (6) SHARED VOTING POWER **
    EACH    
    REPORTING 12,247,229
    PERSON WITH
      (7) SOLE DISPOSITIVE POWER
     
      0
      (8) SHARED DISPOSITIVE POWER **
     
      12,247,229
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        12,247,229
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        9.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

    CUSIP No:      74319F107

     

      (1) NAMES OF REPORTING PERSONS
     
        Heights Capital Management, Inc.
     
      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
    (a)     ¨
    (b)     ¨
     
      (3) SEC USE ONLY
     
      (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
        Delaware
         

    NUMBER OF (5) SOLE VOTING POWER
    SHARES    
    BENEFICIALLY 0  
    OWNED BY (6) SHARED VOTING POWER **
    EACH    
    REPORTING 12,247,229
    PERSON WITH
      (7) SOLE DISPOSITIVE POWER
         
      0
      (8) SHARED DISPOSITIVE POWER **
     
      12,247,229
       

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        12,247,229
       
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ¨
     
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        9.9%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

    CUSIP No:      74319F107

     

    Item 1.

     

    (a)Name of Issuer

     

    Progenity, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    4330 La Jolla Village Drive, Suite 200, San Diego, CA, 92122

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)CUSIP Number

     

    74319F107

     

     

    CUSIP No:      74319F107

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
     
    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
     
    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
     
    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of (i) 8,000,000 Shares, and (ii) Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%.

     

    The Company’s Prospectus Supplement (to Prospectus dated August 6, 2021, Registration No. 333-258301), filed on August 23, 2021, indicates there were 118,347,654 Shares outstanding (excluding Shares underlying the Warrants) as of the completion of the offering of the Shares referred to therein.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

    CUSIP No:      74319F107

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.        Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No:      74319F107

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: August 30, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney, a copy of which is attached Name: Brian Sopinsky
    as Exhibit I hereto Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

    CUSIP No:      74319F107

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney
    II   Joint Filing Agreement

     

     

    CUSIP No:      74319F107

     

    Exhibit I

     

    LIMITED POWER OF ATTORNEY

     

    THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands.

     

    WHEREAS, by agreement dated July 16, 2015, by and between the Company and Heights Capital Management, Inc., the Company expressly authorized Heights Capital Management, Inc. to enter into transactions in certain designated areas as defined in the Discretionary Investment Management Agreement attached hereto marked "Appendix l."

     

    NOW THIS DEED WITNESSETH that William Walmsley, Director of the Company, hereby appoints on behalf of the Company the firm of HEIGHTS CAPITAL MANAGEMENT, INC., which through its officers, directors and employees is hereby formally granted limited power of attorney for the purpose of entering into transactions on behalf and for the account of the Company; and to take all actions on behalf of the Company as may be necessary to consummate such transactions, including but not limited to making, negotiating; signing, endorsing, executing, acknowledging and delivering in the name of the Company all applications, contracts, agreements, notes, statements, certificates, proxies and any other instruments of whatever kind and nature as may be necessary or proper in connection with the entering into of such transactions, instructing the transfer of funds where necessary with respect to such transactions, and performing all of the services specified under the Discretionary Investment Management Agreement with respect to such transactions.

     

    IN WITNESS WHEREOF, the Company has caused this Limited Power of Attorney to take effect on the day and year above written.

     

        CVI Investments, Inc.
         
        By: /s/ William Walmsley   
          William Walmsley, Director

     

     

    CUSIP No:      74319F107

     

    EXHIBIT II

     

    JOINT FILING AGREEMENT

     

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Progenity, Inc., $0.001 par value per share, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

     

    Dated as of August 30, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
       
    By:   Heights Capital Management, Inc. By: /s/ Brian Sopinsky
    pursuant to a Limited Power of Attorney Name: Brian Sopinsky
    Title: Secretary

     

    By: /s/ Brian Sopinsky
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

    Get the next $PROG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROG

    DatePrice TargetRatingAnalyst
    11/4/2021$59.00 → $57.00Overweight → Equal-Weight
    Stephens
    10/14/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PROG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progenity Announces Successful Transfer of Liquid Biopsy Technologies

      SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy. Under the terms of the agreement, Progenity is contributing all assets related to the technologies to newly formed Enumera Molecular, Inc., which intends to develop and commercialize them. Progenity will receive an ownership stake in the company. "Enumera Molecular was founded as a life science tools company focused on developing a scalab

      5/5/22 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progenity downgraded by Stephens with a new price target

      Stephens downgraded Progenity from Overweight to Equal-Weight and set a new price target of $57.00 from $59.00 previously

      11/4/21 7:18:22 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • HC Wainwright & Co. initiated coverage on Progenity with a new price target

      HC Wainwright & Co. initiated coverage of Progenity with a rating of Buy and set a new price target of $4.00

      10/14/21 6:20:58 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity downgraded by Raymond James

      Raymond James downgraded Progenity from Outperform to Market Perform

      6/3/21 7:08:09 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Athyrium Opportunities Iii Co-Invest 1 Lp returned 42,362 units of Series X Preferred Stock to the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:55:13 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Kotzin Brian L. returned 44 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:20 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Mohanty Aditya P. returned 178 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    SEC Filings

    See more
    • Progenity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/20/23 4:05:58 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/12/23 6:06:03 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/9/23 4:02:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Leadership Updates

    Live Leadership Updates

    See more
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Adi Mohanty as Chief Executive Officer

      SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors. "As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success," said Eric d'Esparbes, Chief Financial Officer and interim CEO. "To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase o

      11/9/21 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

      SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi's medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. "As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems of the future. We are delighted that Surbhi Sarna has agreed to join the Progenity Board of Directors to support these efforts," said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder

      6/30/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Financials

    Live finance-specific insights

    See more
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code:

      3/16/22 4:23:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 9763335. A live webcast and archive of the call will be available online from the investor relations section of the compa

      11/3/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      1/12/23 4:46:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      11/18/22 4:30:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13G/A filed by Progenity Inc. (Amendment)

      SC 13G/A - PROGENITY, INC. (0001580063) (Subject)

      2/14/22 3:32:06 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables